China Times: Maywufa Biotech Enters Its 50th Year; Chairman Cheng-Chia Lee: Meeting Change with Change and Breaking New Ground Steadily to Expand Competitiveness
As the Maywufa Biotech Group enters its 50th year, Group founder and Chairman Cheng-Chia Lee led all employees in a Lunar New Year gathering on the 23rd. Lee said that in welcoming 2026, the Year of the Horse, the Group will uphold the spirit of "meeting change with change and breaking new ground steadily," keep strengthening its competitiveness and widening its competitive advantages, and focus on "own brands and deeper channel partnerships," "the joint advance of new biotech drugs and health supplements," and "innovative medical devices for smart medical imaging" to open a new chapter for the biotech industry.
Looking ahead to 2026, Maywufa has a complete, integrated production and sales model spanning R&D, manufacturing, marketing, and sales. Maywufa Vice Chairman Yi-Li Lee said that last year was the first full year of commercial operation for Maywufa's new dual-GMP green building factory. Its stable capacity not only supports the company's multi-brand strategy and successfully meets consumers' diverse needs, but also makes her optimistic that this year's results will reach new highs.
PhytoHealth President Yi-Ling Lee said the company continues to deepen post-marketing research on PG2® (懷特血寶®), which has confirmed that combination therapy can prolong survival in esophageal cancer, and will carry out further in-depth research. PhytoHealth Tong Bao® (懷特痛寶®) continues to accumulate real-world data in Taiwan, targeting demand for post-surgical pain relief, while registration in the European market moves steadily forward. In addition, in the spirit of new drug R&D, the company is moving into health supplements, focusing on post-cancer wellness and expanding in domestic and overseas markets, adding to revenue growth momentum by broadening its product line.
AmCad BioMed President Yi-Li Lee noted that National Health Insurance review of one of its flagship products, the thyroid ultrasound assistance software AmCAD-UT®, continues to progress. On international business development, the company will actively work this year with a leading global AI platform provider and will also take part in the HIMSS healthcare information and management systems conference in the United States in March to increase overall exposure and seize smart healthcare opportunities.